Cargando…
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
The past decade has seen a significant increase in the number of potentially tolerogenic therapies for treatment of new-onset diabetes. However, most treatments are antigen nonspecific, and the mechanism for the maintenance of long-term tolerance remains unclear. In this study, we developed an antig...
Autores principales: | Fife, Brian T., Guleria, Indira, Gubbels Bupp, Melanie, Eagar, Todd N., Tang, Qizhi, Bour-Jordan, Helene, Yagita, Hideo, Azuma, Miyuki, Sayegh, Mohamed H., Bluestone, Jeffrey A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118162/ https://www.ncbi.nlm.nih.gov/pubmed/17116737 http://dx.doi.org/10.1084/jem.20061577 |
Ejemplares similares
-
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
por: Ansari, Mohammed Javeed I., et al.
Publicado: (2003) -
Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal
por: Fife, Brian T., et al.
Publicado: (2009) -
PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4(+) T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes
por: Pauken, Kristen E., et al.
Publicado: (2013) -
Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis
por: Salama, Alan D., et al.
Publicado: (2003) -
A critical role for the programmed death ligand 1 in fetomaternal tolerance
por: Guleria, Indira, et al.
Publicado: (2005)